Immunotherapy Shows 71% Complete Response Rate in Rare Melanoma Subtype
Pembrolizumab achieved remarkable 71% pathological complete response in desmoplastic melanoma patients before surgery.
396 articles in this topic
Pembrolizumab achieved remarkable 71% pathological complete response in desmoplastic melanoma patients before surgery.
Researchers found that stopping HER2 protein degradation significantly improves trastuzumab deruxtecan cancer treatment outcomes.
Scientists discover how to make aggressive triple-negative breast cancer vulnerable to existing targeted therapy.
New research reveals how a rare form of melanoma responds exceptionally well to cutting-edge immunotherapy treatments.
Researchers analyzed 1,294 blood samples to create a comprehensive cancer detection method using cell-free DNA patterns.
Simple blood tests detecting microRNAs show promise for early prostate cancer detection, replacing painful biopsies with precision monitoring.
New EUS techniques enable liquid biopsies, AI-assisted diagnosis, and personalized therapy testing for pancreatic and liver diseases.
ROME trial shows liquid biopsies can effectively guide personalized cancer therapy, potentially replacing invasive tissue biopsies.
Revolutionary liquid biopsy technology uses nanoparticles to detect cancer biomarkers in blood with exceptional precision.
Researchers discover why combining chemotherapy with immunotherapy works better and identify a key resistance mechanism.
Despite decades of research, blood tests for early pancreatic cancer detection remain elusive due to fundamental biological barriers.
New liquid biopsy using exosomes could revolutionize screening for colorectal cancer in people under 50, when traditional screening isn't recommended.